FREGAT网络中致病性CDH1变异携带者的管理:多中心回顾性研究
该多中心回顾性研究描述了FREGAT网络中致病性CDH1变异携带者的管理,主要关注临床结局和病理发现。99例患者中14例索引病例中位生存12.0个月,71.4%诊断时腹膜癌;85例中77例行预防性全胃切除术,术后并发症率37.7%(严重20.8%),标本癌率54.5%(均为pT1a),其中59.5%术前内镜未检出癌。
要点
- 索引病例预后极差,中位生存12.0个月,71.4%诊断时腹膜癌。
- 预防性全胃切除术后并发症率37.7%,严重并发症20.8%。
- 年龄≥40岁和低容量中心是术后并发症预测因素(P=0.030和0.038)。
核心结论
- 在pCDH1vc中,索引病例预后极差。
- 行PTG的患者癌症风险仍高且不可预测,须与PTG的并发症和功能后果权衡。
研究设计与样本
- 回顾性观察性多中心研究,2003年至2021年,来自11个中心,共99例患者包括14例索引病例。
- 数据以中位数(四分位距)或计数(比例)报告,采用常规检验进行单因素分析,二元逻辑回归识别总体和严重术后并发症(Clavien-Dindo≥3级)的风险因素。
主要发现
- 索引病例中位生存12.0(7.6-16.4)个月,71.4%诊断时腹膜癌。
- 剩余85例中77例行PTG,中位年龄34.6(23.7-46.2)岁,ASA评分1占75%,51.9%采用微创入路。
- 术后并发症率37.7%,严重并发症20.8%,年龄≥40岁和低容量中心为预测因素(P=0.030和0.038)。
- PTG后标本癌率54.5%(n=42,均为pT1a),其中59.5%(n=25)术前内镜未检出癌。
临床怎么用
- 对pCDH1vc需个体化决策,平衡PTG的癌症风险降低与并发症及功能后果。
- 年龄≥40岁和低容量中心与PTG后并发症风险升高相关,应纳入术前评估和中心选择。
- 术前内镜可能漏诊早期癌,PTG后标本癌检出率高,提示需充分知情。
局限性
- 回顾性观察性设计,可能存在选择偏倚和信息偏倚。
- 样本量有限(99例),来自11个中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the management of pathogenic CDH1 variant carriers (pCDH1vc) within the FREGAT (FRench Eso-GAsTric tumor) network. Primary objective focused on clinical outcomes and pathological findings, Secondary objective was to identify risk factor predicting postoperative morbidity (POM). BACKGROUND: Prophylactic total gastrectomy (PTG) remains the recommended option for gastric cancer risk management in pCDH1vc with, however, endoscopic surveillance as an alternative. METHODS: A retrospective observational multicenter study was carried out between 2003 and 2021. Data were reported as median (interquartile range) or as counts (proportion). Usual tests were used for univariate analysis. Risk factors of overall and severe POM (ie, Clavien-Dindo grade 3 or more) were identified with a binary logistic regression. RESULTS: A total of 99 patients including 14 index cases were reported from 11 centers. Median survival among index cases was 12.0 (7.6-16.4) months with most of them having peritoneal carcinomatosis at diagnosis (71.4%). Among the remaining 85 patients, 77 underwent a PTG [median age=34.6 (23.7-46.2), American Society of Anesthesiologists score 1: 75%] mostly via a minimally invasive approach (51.9%). POM rate was 37.7% including 20.8% of severe POM, with age 40 years and above and low-volume centers as predictors ( P =0.030 and 0.038). After PTG, the cancer rate on specimen was 54.5% (n=42, all pT1a) of which 59.5% had no cancer detected on preoperative endoscopy (n=25). CONCLUSIONS: Among pCDH1vc, index cases carry a dismal prognosis. The risk of cancer among patients undergoing PTG remained high and unpredictable and has to be balanced with the morbidity and functional consequence of PTG.
引用
- Bres C, Voron T, Benhaim L, et al. Management of Pathogenic CDH1 Variant Carriers Within the FREGAT Network: A Multicentric Retrospective Study. Ann Surg. 2022. PMID: 35856494. doi:10.1097/SLA.0000000000005626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。